OCS Stock Overview
Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Oculis Holding AG Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$12.92 |
| 52 Week High | US$14.50 |
| 52 Week Low | US$9.05 |
| Beta | 0.18 |
| 1 Month Change | 17.35% |
| 3 Month Change | 1.73% |
| 1 Year Change | 4.03% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 33.20% |
Recent News & Updates
Recent updates
Shareholder Returns
| OCS | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 8.1% | 3.0% | 0.3% |
| 1Y | 4.0% | 12.0% | 24.2% |
Return vs Industry: OCS underperformed the US Pharmaceuticals industry which returned 12.5% over the past year.
Return vs Market: OCS underperformed the US Market which returned 22.8% over the past year.
Price Volatility
| OCS volatility | |
|---|---|
| OCS Average Weekly Movement | 4.5% |
| Pharmaceuticals Industry Average Movement | 9.9% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: OCS has not had significant price volatility in the past 3 months.
Volatility Over Time: OCS's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 36 | Riad Sherif | oculis.com |
Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company’s lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis. The company is based in Zug, Switzerland.
Oculis Holding AG Fundamentals Summary
| OCS fundamental statistics | |
|---|---|
| Market cap | US$535.20m |
| Earnings (TTM) | -US$97.56m |
| Revenue (TTM) | US$970.05k |
554.7x
P/S Ratio-5.5x
P/E RatioIs OCS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| OCS income statement (TTM) | |
|---|---|
| Revenue | CHF883.00k |
| Cost of Revenue | CHF29.25m |
| Gross Profit | -CHF28.36m |
| Other Expenses | CHF60.44m |
| Earnings | -CHF88.80m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.13 |
| Gross Margin | -3,212.23% |
| Net Profit Margin | -10,056.85% |
| Debt/Equity Ratio | 0% |
How did OCS perform over the long term?
See historical performance and comparison